Instituto de Oncología de Rosario

Recent papers from Instituto de Oncología de Rosario

1. Geographic Variation in Diagnosis, Treatment, and Outcomes of Adrenocortical Carcinoma in the Americas: A Narrative ReviewEndocrine Oncology · 2026
2. 8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)The Breast · 2026
3. Pembrolizumab Plus Chemotherapy for Cervical CancerJAMA Oncology · 2026
4. Sociodemographic and Clinicopathologic Characteristics of Patients With Invasive Breast Cancer in Latin America: The LATINA Breast Cohort (LACOG 0615/MO39485)JCO Global Oncology · 2026
5. TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2 ‐like macrophages induced by tumor microenvironment‐derived TGFβ1The Journal of Pathology · 2026
6. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trialAnnals of Oncology · 2026
7. Expanding indications for PARP inhibitors in prostate cancerUrologic Oncology Seminars and Original Investigations · 2026
8. Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trialInternational Journal of Gynecological Cancer · 2026
9. Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation BarriersInternational Journal of Molecular Sciences · 2026
10. Oral Melanoma: A South American Collaborative Series of 21 CasesHead and Neck Pathology · 2026
11. TroFuse-022/ENGOT-ov84/GOG-3103 part 2: A phase 3 study of maintenance therapy with sacituzumab tirumotecan ± bevacizumab vs standard of care following second-line platinum-based doublet chemotherapy for platinum-sensitive recurrent ovarian cancer.Journal of Clinical Oncology · 2026
12. Doctor, am I cured? Characteristics of long-term survivors with advanced melanoma treated with immunotherapy.Journal of Clinical Oncology · 2026
13. Recurrence of ductal carcinoma in situ: A large South American multicenter analysis.Journal of Clinical Oncology · 2026
14. Development of a multivariable prognostic model for pathological response using anatomical and pathological variables in early triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: Initial results.Journal of Clinical Oncology · 2026
15. Impact of pembrolizumab infusion timing on outcomes in early-stage triple-negative breast cancer: A real-world exploratory analysis (Neo-Real).Journal of Clinical Oncology · 2026
16. Novel Cu(II)-complex loaded Eudragit® nanoparticles: design, synthesis, characterization, and enhanced antitumor activity against triple-negative breast cancerInternational Journal of Pharmaceutics · 2026
17. Ten-year subtype survival and systemic–therapy pathways analysis after breast-cancer recurrence in the LACRN MPBC multicountry cohort studyThe Lancet Regional Health - Americas · 2026
18. Abstract 3283: Metabolic crosstalk between fatty acid oxidation and glycolysis underlies glioblastoma viabilityCancer Research · 2026
19. Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway InhibitorsEuropean Urology Open Science · 2026
20. Conventional-dose chemotherapy as first salvage in germ cell tumors: Outcomes from an Ibero-American multi-institutional cohort.Journal of Clinical Oncology · 2026